Clinical trials: Antipsychotic
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute…
- Trial name
- NOVA2 (NCT07363577)
- Testing
- LB-102 (50 mg tablet), LB-102 (100 mg tablet)
- Where
- 13 sites in United States
- Volunteers
- 456 people
- Sponsor
- LB Pharmaceuticals Inc.
Stroke
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and…
- Trial name
- NCT04002700
- Testing
- Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
- Where
- United States
- Volunteers
- 1,234,412 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Disorder, Manic Episode
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo in treating mania during 3 weeks of treatment in patients with Bipolar I Disorder who suffer from…
- Trial name
- NCT00249236
- Testing
- Risperidone, oral tablets
- Volunteers
- 291 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment.
- Trial name
- NCT03351244
- Testing
- BI 409306
- Where
- 59 sites in United States, Canada and 5 more
- Volunteers
- 264 people
- Sponsor
- Boehringer Ingelheim
Schizoaffective Disorder, Schizophrenia
A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
The purpose of this study is to see if differences exist in outcome in patients with schizophrenia or schizoaffective disorder who were switched from other antipsychotics to ziprasidone.
- Trial name
- NCT00649064
- Testing
- Ziprasidone
- Where
- 3 sites in Taiwan
- Volunteers
- 46 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
- Trial name
- NCT04461119
- Testing
- Evenamide
- Where
- 14 sites in United States, India
- Volunteers
- 138 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia, Bipolar Disorder
Spanish Validation of Tool Questionnaire to Assess Patients´Perception About Antipsychotic Treatment
Non-interventional, prospective study to validate Spanish version of TOOL questionnaire in patients with schizophrenia and bipolar disorder under antipsychotic treatment
- Trial name
- TOOL (NCT00692133)
- Where
- 32 sites in Spain
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Schizophrenia
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
The primary objective of this randomized trial was to investigate whether early initiation of treatment with Risperdal Consta after an acute episode was not inferior to the routine approach (oral treatment for 12 weeks followed…
- Trial name
- NCT00216671
- Testing
- early initiation of treatment with Risperdal Consta, routine initiation of treatment with Risperdal Consta
- Where
- 31 sites in Denmark, Finland and 8 more
- Volunteers
- 220 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Psychotic Disorders, Schizophrenia
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after…
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT02087579
- Testing
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation
- Where
- 24 sites in United States, Argentina and 5 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
- Trial name
- NCT01625897
- Testing
- MP-214, Risperidone
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia, Psychotic Disorders
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
The primary purpose of the study is to show that treatment with an injectable formulation of risperidone is not less effective than and has a similar safety profile to risperidone tablets in patients with chronic schizophrenia.
- Trial name
- NCT00249223
- Testing
- Risperidone Long acting injectable
- Volunteers
- 641 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting.
- Trial name
- PLEASURE (NCT01160679)
- Where
- 12 sites in South Korea
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- SWN-K (NCT00749970)
- Where
- 14 sites in Spain
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Schizophrenia
Long-Term Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626872
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.
- Trial name
- NCT01448720
- Testing
- Paliperidone palmitate
- Where
- 12 sites in Brazil, Colombia and 1 more
- Volunteers
- 142 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Antipsychotic-induced Weight Gain
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
This study will investigate if there is any difference in the amount of weight gained by participants taking olanzapine with CORT118335 compared with olanzapine with placebo (a dummy test medicine which looks like CORT118335 but…
- Trial name
- NCT03877562
- Testing
- Olanzapine, CORT118335
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of…
- Trial name
- NCT01192880
- Testing
- Bitopertin, Antipsychotics
- Where
- 103 sites in United States, Bulgaria and 5 more
- Volunteers
- 625 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals